Early Theranos Investor Stands by Blood Testing Startup
Jurvetson Supportive of Theranos Even Without Answers
This article is for subscribers only.
Steve Jurvetson, whose venture firm DFJ was an early investor in Theranos Inc., said the health-care startup has his support, though he can’t address the questions that have arisen about the accuracy of its technology.
“We definitely stand behind Theranos, in the sense of, we are an investor and we want them to succeed,” Jurvetson said in an with Emily Chang for Bloomberg Television. “We don’t, though, have the answers to the questions that are swirling around right now.”